# Durable Response to Pembrolizumab With Chemotherapy in EGFR-Mutated Squamous Cell Lung Cancer: A Case Report

## TL;DR

A patient with EGFR-mutated squamous cell lung cancer showed a long-term response to pembrolizumab plus chemotherapy, suggesting personalized treatment may be more effective in some cases.

## Contribution

This case report highlights the potential efficacy of pembrolizumab plus chemotherapy in EGFR-mutated squamous cell lung cancer when standard therapy may not be optimal.

## Key findings

- A patient with EGFR-mutated squamous cell lung cancer showed durable response to pembrolizumab plus chemotherapy.
- No recurrence was observed three years after treatment initiation.
- The case emphasizes the importance of personalized treatment based on patient-specific factors.

## Abstract

Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) is the standard treatment for EGFR-mutated non-small cell lung cancer (NSCLC), although a small subset of patients does not respond to EGFR-TKI, especially in patients with a smoking history and squamous cell histology. Additionally, even given an initial good response, acquired resistance to EGFR-TKI is inevitable. More individualized treatment could be necessary in certain types of EGFR-mutated NSCLC. We herein report a case of EGFR-mutated metastatic lung squamous cell carcinoma with a high tumor proportion score (TPS) of programmed death ligand 1 (PD-L1), where chemotherapy plus pembrolizumab therapy had a durable efficacy. In this case, chemotherapy plus pembrolizumab therapy was administered, though EGFR-TKI is the standard first-line therapy of EGFR-mutated NSCLC. Three years after treatment initiation, no sign of recurrence was observed. This case suggests that a detailed evaluation of a patient's background is important in making an effective personalized therapeutic strategy.